[1. THE LANCET HAEMATOLOGY. A roadmap for European research. Lancet Haematol. 2016; 3(3):e99.10.1016/S2352-3026(16)00025-9]Search in Google Scholar
[2. TOMULEASA C., FUJI S., CUCUIANU A., KAPP M., PILECZKI V., PETRUSHEV B., et al. MicroRNAs as biomarkers for graft-versus-host disease following allogeneic stem cell transplantation. Ann Hematol. 2015; 94(7):1081-92.10.1007/s00277-015-2369-025900787]Search in Google Scholar
[3. BRAICU C., TOMULEASA C., MONROIG P., CUCUIANU A., BERINDAN-NEAGOE I., CALIN G.A. Exosomes as divine messengers: are they the Hermes of modern molecular oncology? Cell Death Differ. 2015; 22(1):34-45.10.1038/cdd.2014.130426277725236394]Search in Google Scholar
[4. BERINDAN-NEAGOE I., MONROIG P DEL C., PASCULLI B., CALIN G.A. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin. 2014; 64(5):311-36.10.3322/caac.21244446119825104502]Search in Google Scholar
[5. TOMULEASA C., AKIN-ABAYOMI E., DIMA D., TEFAS C., IRIMIE A., PETRUSHEV B., et al. Do lymphomas have an autoimmune background and how can we increase the sensitivity of the diagnosis of primary pancreatic lymphoma with relatively small samples? J Gastrointestin Liver Dis. 2015; 24(3):391-2.]Search in Google Scholar
[6. GREWAL R., CUCUIANU A., SWANEPOEL C., DIMA D., PETRUSHEV B., POP B., et al. The role of microRNAs in the pathogenesis of HIV-related lymphomas. Crit Rev Clin Lab Sci. 2015; 52(5):232-41.10.3109/10408363.2015.103006326218036]Search in Google Scholar
[7. BRAMMER J.E., KHOURI I., GABALLA S., ANDERLINI P., TOMULEASA C., AHMED S., et al. Outcomes of Haploidentical Stem Cell Transplantation for Lymphoma with Melphalan-Based Conditioning. Biol Blood Marrow Transplant. 2016; 22(3):493-8.10.1016/j.bbmt.2015.10.01526497906]Search in Google Scholar
[8. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., ORBAN C., et al. Haploidentical Donors: Can Faster Transplantation Be Life-Saving for Patients with Advanced Disease? Acta Haematol. 2016; 135(4):211-216.10.1159/00044346926914538]Search in Google Scholar
[9. TANASE A., TOMULEASA C., MARCULESCU A., BARDAS A., COLITA A., CIUREA S.O. First successful haploidentical stem cell transplantation in Romania. Rom J Intern Med 2016, in press.10.1515/rjim-2016-0021725221627658169]Search in Google Scholar
[10. PETRUSHEV B., BOCA S., SIMON T., BERCE C., FRINC I., DIMA D., et al. Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy. Int J Nanomedicine. 2016; 11:641-60.]Search in Google Scholar
[11. SUARASAN S., SIMON T., BOCA S., TOMULEASA C., ASTILEAN S. Gelatin coated gold nanoparticles as carriers of FLT3 inhibitors for acute myeloid leukemia treatment. Chem Biol Drug Des. 2016; doi: 10.1111/cbdd.12725.]Search in Google Scholar
[12. SIMON T., TOMULEASA C., BOJAN A., BERINDAN-NEAGOE I., BOCA S., ASTILEAN S. Design of FLT3 Inhibitor - Gold Nanoparticle Conjugates as Potential Therapeutic Agents for the Treatment of Acute Myeloid Leukemia. Nanoscale Res Lett. 2015; 10(1):466.10.1186/s11671-015-1154-2466684526625890]Search in Google Scholar
[13. CIUREA S.O., ZHANG M.J., BACIGALUPO A.A., BASHEY A., APPELBAUM F.R., ALJITAWI O.S., et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015; 126(8):1033-40.10.1182/blood-2015-04-639831454322326130705]Search in Google Scholar
[14. TOMULEASA C., DIMA D., FRINC I., PATIU M., PETRUSHEV B., CUCUIANU A., et al. BCR-ABL1 T315I mutation, a negative prognostic factor for the terminal phase of chronic myelogenous leukemia treated with first- and second-line tyrosine kinase inhibitors, might be an indicator of allogeneic stem cell transplant as the treatment of choice. Leuk Lymphoma. 2015; 56(2):546-7.10.3109/10428194.2014.94058225012945]Search in Google Scholar
[15. ALONSO S., SU M., JONES J.W., GANGULY S., KANE M.A., JONES R.J., et al. Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes. Oncotarget. 2015; 6(17):14905-12.10.18632/oncotarget.3614455812425915157]Search in Google Scholar
[16. SU M., ALONSO S., JONES J.W., YU J., KANE M.A., JONES R.J., et al. All-Trans Retinoic Acid Activity in Acute Myeloid Leukemia: Role of Cytochrome P450 Enzyme Expression by the Microenvironment. PLoS One. 2015; 10(6):e0127790.10.1371/journal.pone.0127790445789326047326]Search in Google Scholar
[17. MCCORMACK E., HAALAND I., VENAS G., FORTHUN R.B., HUSEBY S., GAUSDAL G., et al. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012; 26(5):910-7.10.1038/leu.2011.31522064349]Search in Google Scholar
[18. MCCORMACK E., MUJIC M., OSDAL T., BRUSERUD Ø., GJERTSEN B.T. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013; 121(7):e34-42.10.1182/blood-2012-05-42955523243270]Search in Google Scholar
[19. TANASE A., SCHMITZ N., STEIN H., BOUMENDIL A., FINEL H., CASTAGNA L., et al. Allogeneic and autologous stem cell transplantation for hepatosplenic T-cell lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Leukemia. 2015; 29(3):686-8.10.1038/leu.2014.28025234166]Search in Google Scholar
[20. TRIFA A.P., POPP R.A., CUCUIANU A., BANESCU C., TEVET M., MARTIN B., et al. CALR versus JAK2 mutated essential thrombocythaemia - a report on 141 patients. Br J Haematol. 2015; 168(1):151-3.10.1111/bjh.1307625103987]Search in Google Scholar
[21. TOMULEASA C., BRAICU C., IRIMIE A., CRACIUN L., BERINDAN-NEAGOE I. Nanopharmacology in translational hematology and oncology. Int J Nanomedicine. 2014; 9:3465-79.]Search in Google Scholar